UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000034453
Receipt number R000039271
Scientific Title Clinical implications of postoperative carbohydrate antigen 19-9 as a serological indicator of positive resection margin and occult distant metastasis in patients with resected pancreatic cancer
Date of disclosure of the study information 2018/10/11
Last modified on 2018/10/11 16:54:27

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical implications of postoperative carbohydrate antigen 19-9 as a serological indicator of positive resection margin and occult distant metastasis in patients with resected pancreatic cancer

Acronym

Clinical implications of postoperative carbohydrate antigen 19-9 in patients with resected pancreatic cancer

Scientific Title

Clinical implications of postoperative carbohydrate antigen 19-9 as a serological indicator of positive resection margin and occult distant metastasis in patients with resected pancreatic cancer

Scientific Title:Acronym

Clinical implications of postoperative carbohydrate antigen 19-9 in patients with resected pancreatic cancer

Region

Japan


Condition

Condition

pancreatic ductal adenocarcinoma

Classification by specialty

Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To investigate the prognostic value of elevated Post-CA 19-9 and its preoperative and postoperative clinical significance in patients with macroscopically resectable pancreatic cancer.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase



Assessment

Primary outcomes

Independent prognostic factors were identified using univariate and multivariate Cox-proportional hazard models including pathological and postoperative clinical variables.

Key secondary outcomes

Univariate and multivariate logistic regression analysis were used to identify factors that were independent predictive factors of elevated Post-CA 19-9.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with surgical resection for pancreatic ductal adenocarcinoma between January 2008 and December 2016 were included in the analysis.

Key exclusion criteria

Patients with macroscopically positive resection margin or distant metastasis were excluded.
Patients with Pre-CA 19-9 < 5 U/ml were excluded.
CA 19-9 values were not included in the analysis if serum total bilirubin was >2.0 mg/dl at the time of assay.

Target sample size

166


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takagi Chisato

Organization

Tochigi Cancer Center

Division name

Hepato-Biliary-Pancreatic Surgery

Zip code


Address

4-9-13, Yohnan, Utsunomiya, Tochigi 320-0834, Japan

TEL

028-658-5151

Email

chtakagi@tochigi-cc.jp


Public contact

Name of contact person

1st name
Middle name
Last name Takagi Chisato

Organization

Tochigi Cancer Center

Division name

Hepato-Biliary-Pancreatic Surgery

Zip code


Address

4-9-13, Yohnan, Utsunomiya, Tochigi 320-0834, Japan

TEL

028-658-5151

Homepage URL


Email

chtakagi@tochigi-cc.jp


Sponsor or person

Institute

Tochigi Cancer Center

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 10 Month 11 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2018 Year 05 Month 01 Day

Date of IRB


Anticipated trial start date

2018 Year 05 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This is a retrospective cohort study evaluated patient data collected at the Tochigi Cancer Center.
Patients with surgical resection for PDCA between January 2008 and December 2016 were included in the analysis.


Management information

Registered date

2018 Year 10 Month 11 Day

Last modified on

2018 Year 10 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039271


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name
2018/10/11 ad2008.csv